Areteia Therapeutics is a new biotechnology company committed to putting asthma patients in better control of their disease—and back in control of their lives—with the first potential oral drug for eosinophilic asthma.

Maverick Capital

Population Health Partners

Access Biotechnology

ARCH Venture Partners

Google Ventures

Sanofi

Saturn Partners

Bain Capital Life Sciences

AreteiaTx

“I am excited that Dan has been appointed to our board,” said Jorge Bartolome, President and Chief Executive Officer of Areteia. “He is an incredibly accomplished executive whose depth of biotech experience, proven leadership and scientific expertise will be invaluable to me and the Board of Directors as we focus on delivering on the Company’s strategy and further advancing the Phase III program for dexpramipexole, the first potential oral drug for eosinophilic asthma.”

Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma - We are proud to announce that this will support significant expansion of the existing program, including adding clinical development in Japan along with several additional global markets, expansion of manufacturing activities and additional life-cycle management including development of a once-daily formulation.
Viking Global Investors and Marshall Wace to join the syndicate. More information here: https://lnkd.in/eUBs-de8

We are pleased to announce that results from the phase II EXHALE-1 study of oral dexpramipexole in eosinophilic asthma have been published online in the Journal of Allergy and Clinical Immunology. 

Jefferies Healthcare Conference (@Marriott Marquis in NYC) 

7-9th June 2023

Please come and meet Jorge Bartolome our CEO, Chris Courts our CFO, and Eric Bradford our CMO. We are presenting Wednesday, June 7th at 4:00-4:25 PM in Track 9.

We look forward to seeing you, and discussing all things eosinophilic asthma.

https://lnkd.in/gFfcbnWw

#healthcare #asthma #eosinophils


Areteia Therapeutics is a biotechnology company focused on developing innovative treatments for cognitive impairment associated with neuropsychiatric conditions.

COM:ARETEIATX

Areteia Therapeutics

Filings Not Available